HER2-Positive Breast Cancer: A Literature Review
DOI:
10.29303/jbt.v25i4a.10991Published:
2025-12-16Downloads
Abstract
Breast cancer remains a malignancy with high global mortality rates. Approximately 15-20% of these cases are Human Epidermal Growth Factor Receptor 2 (HER2) positive subtype, characterized by aggressiveness, high risk of metastasis, and poor prognosis if left untreated. This literature review aims to discuss the pathophysiology, diagnostic methods, and recent advancements in the management of HER2-positive breast cancer. The study utilized a literature review method, sourcing data from PubMed, Google Scholar, and ScienceDirect databases. A total of 23 literatures published within the last 5-10 years were selected based on inclusion criteria. Overexpression of HER2 protein triggers the activation of MAPK and PI3K/AKT/mTOR signaling pathways, stimulating uncontrolled cell proliferation. Diagnosis is established via Immunohistochemistry (IHC) and confirmed by In Situ Hybridization (ISH) following ASCO/CAP 2018 guidelines. Current management shows a significant shift; neoadjuvant and first-line advanced stage therapies prioritize dual blockade (Trastuzumab and Pertuzumab). Furthermore, the new generation Antibody-Drug Conjugate (ADC), Trastuzumab Deruxtecan (T-DXd), has demonstrated superior efficacy compared to T-DM1 as a second-line therapy. Comprehensive understanding of HER2 molecular biology and advances in targeted therapy have transformed the clinical landscape, increasing survival rates and significantly improving the prognosis of HER2-positive breast cancer patients.
Keywords:
Breast cancer Cancer HER2References
Agostinetto, E., Curigliano, G., & Piccart, M. (2024). Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar. Cell Reports Medicine, 5(6), 101575. https://doi.org/10.1016/j.xcrm.2024.101575
Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2020). HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. Journal of Pathology and Translational Medicine, 54(1), 34–44. https://doi.org/10.4132/jptm.2019.11.03
Benacka, R., Szabóová, D., Gul’ašová, Z., Hertelyová, Z., & Radonák, J. (2022). Classic and New Markers in Diagnostics and Classification of Breast Cancer. 70(8), 515–517. 10.3390/cancers14215444
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Burguin, A., Diorio, C., Durocher, F., 2021. Breast Cancer Treatments: Updates and New Challenges. J. Pers. Med. 11. https://doi.org/10.3390/jpm11080808
Cheng, X. (2024). A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes, 15(7). https://doi.org/10.3390/genes15070903
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H. H., Haydon, R. C., He, T. C., & Ren, G. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes and Diseases, 5(2), 77–106. https://doi.org/10.1016/j.gendis.2018.05.001
Gagliato, D. D. M., Leonardo, D., Jardim, F., Pereira, M. S., & Hortobagyi, G. N. (2016). Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2 + breast cancer Introduction : Pathways to Trastuzumab. Oncotarget, 7(39). 10.18632/oncotarget.7043
Harvey N. Mayrovitz, P. (2022). Chapter 3: Subtypes of Breast Cancer. In Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/36122153/
Lawrenti, H. (2023). Terapi Kanker Payudara Stadium Lanjut HER2 (+). Cermin Dunia Kedokteran, 50(10), 565–569. https://doi.org/10.55175/cdk.v50i10.915
Li, J., Wang, X., Wang, S., Wang, S., Wang, T., Liu, Y., & Geng, C. (2023). Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer ( 2023 edition ). 1–10. https://doi.org/10.21037/tbcr-22-48
Maiese, K. (2017). Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss. In Current Neurovascular Research (Vol. 14, Issue 4, pp. 415–420). https://doi.org/http://dx.doi.org/10.2174/1567202614666171116102911
Miricescu, D., Totan, A., Stanescu-Spinu, I. I., Badoiu, S. C., Stefani, C., & Greabu, M. (2021). PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. International Journal of Molecular Sciences, 22(1), 1–24. https://doi.org/10.3390/ijms22010173
National Cancer Institute. (2025). Cancer Stat Facts: Female Breast Cancer Subtypes. National Cancer Institute (NCI). https://seer.cancer.gov/statfacts/html/breast-subtypes.html
Roy, M., Fowler, A. M., Ulaner, G. A., & Mahajan, A. (2023). Molecular Classification of Breast Cancer. PET Clinics, 18(4), 441–458. https://doi.org/10.1016/j.cpet.2023.04.002
Rubin, E., Shan, K. S., Dalal, S., Thaw Dar, N. N., McLish, O., Salzberg, M., & Pico, B. A. (2024). Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers. International Journal of Molecular Sciences, 25(2). https://doi.org/10.3390/ijms25020849
Setiawan, I. M. A. (2023). Peran Pemeriksaan Imunohistokimia dalam Diagnosis dan Prognosis Kanker Payudara. Cermin Dunia Kedokteran, 50(8), 443–446. https://doi.org/10.55175/cdk.v50i8.667
Swain, S. M., Miles, D., Kim, S. B., Im, Y. H., Im, S. A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J., Agajanian, R., Ahmad, R., Aktas, B., Alencar, V. H., Youn Oh, D. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 21(4), 519–530. https://doi.org/10.1016/S1470-2045(19)30863-0
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., Penault-Llorca, F., Viale, G., Andrè, F., & Curigliano, G. (2020). HER2-Low breast cancer: Pathological and clinical landscape. Journal of Clinical Oncology, 38(17), 1951–1962. https://doi.org/10.1200/JCO.19.02488
Tomasello, G., Gambini, D., Petrelli, F., Azzollini, J., Arcanà, C., Ghidini, M., Peissel, B., Manoukian, S., & Garrone, O. (2022). Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. ESMO Open, 7(4), 100531. https://doi.org/10.1016/j.esmoop.2022.100531
Vyberg, M., Nielsen, S., Røge, R., Sheppard, B., Ranger-Moore, J., Walk, E., Gartemann, J., Rohr, U. P., & Teichgräber, V. (2015). Immunohistochemical expression of HER2 in breast cancer: Socioeconomic impact of inaccurate tests. BMC Health Services Research, 15(1), 1–9. https://doi.org/10.1186/s12913-015-1018-6
Widiana, I. K., & Irawan, H. (2020). Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific Journal of Cancer Care, 5(4), 281–285. https://doi.org/10.31557/apjcc.2020.5.4.281-285
Zubair, M., Wang, S., & Ali, N. (2021). Advanced Approaches to Breast Cancer Classification and Diagnosis. Frontiers in Pharmacology, 11(February), 1–24. https://doi.org/10.3389/fphar.2020.632079
License
Copyright (c) 2025 Muhammad Fikri Adidaifa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
